Intellia Therapeutics (NTLA) Reports Q1 Loss of $0.49/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. DECK
2. RNG
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Intellia Therapeutics (NTLA) Reports Q1 Loss of $0.49/Share

Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update

May 2, 2019 7:30 AM EDT

Remains on track to submit investigational new drug application in 2020 for its first systemically delivered CRISPR/Cas9-based therapy, NTLA-2001, for treatment of transthyretin amyloidosisExpects to nominate first engineered cell therapy development candidate for treatment of acute myeloid leukemia by end of 2019First demonstration of CRISPR/Cas9-based, targeted insertion of a Factor 9 gene in the liver of non-human primates achieves normal circulating human Factor IX protein levels Ends quarter with strong cash position of $297 million

CAMBRIDGE, Mass., May 02, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:... More